{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:10Z","timestamp":1780987990745,"version":"3.54.1"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral T-cell lymphoma (PTCL) represents a heterogeneous group of lymphomas with a generally poor prognosis. With recent advances in our understanding of the cellular origins and genomic profiles of PTCL, lymphomas of follicular helper T-cell (TFH) origins with distinct markers and gene mutation profiles are categorized as a single entity, nodal TFH lymphomas\u2014angioimmunoblastic type, follicular type, and not otherwise specified, in the fifth edition of the WHO classification. The standard treatment for PTCL has been CHOP or CHOP-like regimens for decades. The ECHELON-2 trial marked a significant advance in the treatment of PTCL by demonstrating significantly longer survival with BV-CHP than with CHOP for CD30-positive PTCL, establishing BV-CHP as the standard of care for this group of patients. However, attempts to integrate other novel agents into CHOP have largely been unsuccessful, primarily due to increased toxicity, and, thus, CHOP remains the standard treatment for CD30-negative PTCL. Upfront autologous stem cell transplantation is currently controversial, and ongoing randomized controlled trials are expected to clarify its role. With advances in our understanding of the molecular and genetic characteristics of PTCL and potential predictive biomarkers, the future development of treatment will focus on more stratified approaches, and ongoing trials are expected to provide further insights into optimizing these treatment strategies.<\/jats:p>","DOI":"10.1093\/jjco\/hyaf158","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:49:29Z","timestamp":1758628169000},"page":"24-32","source":"Crossref","is-referenced-by-count":2,"title":["Recent advances and future perspectives in frontline treatment of peripheral T-cell lymphoma"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-2030","authenticated-orcid":false,"given":"Yuko","family":"Shirouchi","sequence":"first","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , 3-8-31, Ariake, Koto-ku, 135-8550, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2026012223575830500_ref1","doi-asserted-by":"publisher","DOI":"10.4102\/jcmsa.v2i1.75","volume-title":"Haematolymphoid Tumours: WHO Classification of Tumours","year":"2024","edition":"5th Edition"},{"key":"2026012223575830500_ref2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: A report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"2026012223575830500_ref3","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026012223575830500_ref4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"2026012223575830500_ref5","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"2026012223575830500_ref6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"key":"2026012223575830500_ref7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"2026012223575830500_ref8","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"key":"2026012223575830500_ref9","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"2026012223575830500_ref10","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"2026012223575830500_ref11","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"2026012223575830500_ref12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood.2021015019","article-title":"DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS","volume":"140","author":"Herek","year":"2022","journal-title":"Blood"},{"key":"2026012223575830500_ref13","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"2026012223575830500_ref14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single north American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"key":"2026012223575830500_ref15","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"2026012223575830500_ref16","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"2026012223575830500_ref17","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"2026012223575830500_ref18","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/cncr.30416","article-title":"A prospective cohort study of patients with peripheral T-cell lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"2026012223575830500_ref19","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021015114","article-title":"Impact of etoposide and ASCT on survival among patients aged &lt;65 years with stage II to IV PTCL: a population-based cohort study","volume":"140","author":"Brink","year":"2022","journal-title":"Blood"},{"key":"2026012223575830500_ref20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"2026012223575830500_ref21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"key":"2026012223575830500_ref22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026012223575830500_ref23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s12185-017-2286-1","article-title":"Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: A phase I\/II and pharmacokinetics study","volume":"106","author":"Maruyama","year":"2017","journal-title":"Int J Hematol"},{"key":"2026012223575830500_ref24","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: A non-randomised, phase 1b\/2 study","volume":"2","author":"Dupuis","year":"2015","journal-title":"Lancet Haematol"},{"key":"2026012223575830500_ref25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: Results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026012223575830500_ref26","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1200\/JCO.23.01687","article-title":"Romidepsin plus cyclophosphamide, doxorubicin, vincristine, and prednisone versus cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated peripheral T-cell lymphoma: Final analysis of the Ro-CHOP trial","volume":"42","author":"Camus","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026012223575830500_ref27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41375-022-01780-1","article-title":"Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated peripheral T-cell lymphoma: Results of the PTCL13 phase Ib\/II study","volume":"37","author":"Chiappella","year":"2023","journal-title":"Leukemia"},{"key":"2026012223575830500_ref28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bjh.12326","article-title":"Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma","volume":"162","author":"Oki","year":"2013","journal-title":"Br J Haematol"},{"key":"2026012223575830500_ref29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"2026012223575830500_ref30","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1182\/blood.2022018254","article-title":"Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL","volume":"141","author":"Ruan","year":"2023","journal-title":"Blood"},{"key":"2026012223575830500_ref31","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026012223575830500_ref32","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1111\/cas.13340","article-title":"Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma","volume":"108","author":"Maruyama","year":"2017","journal-title":"Cancer Sci"},{"key":"2026012223575830500_ref33","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/bloodadvances.2023010441","article-title":"Pooled analysis of pralatrexate single-agent studies in patients with relapsed\/refractory peripheral T-cell lymphoma","volume":"8","author":"O'Connor","year":"2024","journal-title":"Blood Adv"},{"key":"2026012223575830500_ref34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/bloodadvances.2023011095","article-title":"Pralatrexate injection combined with CHOP for treatment of PTCL: Results from the Fol-CHOP dose-finding phase 1 trial","volume":"8","author":"Iyer","year":"2024","journal-title":"Blood Adv"},{"key":"2026012223575830500_ref35","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/blood-2018-99-110429","article-title":"Final analysis of the front-line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant","volume":"132","author":"Francesco d'Amore","year":"2018","journal-title":"Blood"},{"key":"2026012223575830500_ref36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: The DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"2026012223575830500_ref37","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1182\/blood-2018-99-112076","article-title":"Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (PTCL) in previously untreated young and elderly patients: Pooled analysis of the international ACT-1\/2 phase III trials","volume":"132","author":"Bettina Altmann","year":"2018","journal-title":"Blood"},{"key":"2026012223575830500_ref38","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"2026012223575830500_ref39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bjh.18885","article-title":"Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma","volume":"202","author":"Stuver","year":"2023","journal-title":"Br J Haematol"},{"key":"2026012223575830500_ref40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv"},{"key":"2026012223575830500_ref41","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.ejca.2012.06.003","article-title":"Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"},{"key":"2026012223575830500_ref42","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: The CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2026012223575830500_ref43","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/annonc\/mdv624","article-title":"A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"2026012223575830500_ref44","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1182\/bloodadvances.2023011526","article-title":"Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: A phase 1 trial","volume":"8","author":"Haverkos","year":"2024","journal-title":"Blood Adv"},{"key":"2026012223575830500_ref45","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012223575830500_ref46","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/10428194.2018.1563691","article-title":"Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis","volume":"60","author":"Al-Mansour","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2026012223575830500_ref47","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026012223575830500_ref48","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","article-title":"Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study","volume":"107","author":"Garc\u00eda-Sancho","year":"2022","journal-title":"Haematologica"},{"key":"2026012223575830500_ref49","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: Prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"key":"2026012223575830500_ref50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00277-016-2891-8","article-title":"Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP\/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment","volume":"96","author":"Kitahara","year":"2017","journal-title":"Ann Hematol"},{"key":"2026012223575830500_ref51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"key":"2026012223575830500_ref52","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","article-title":"First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients","volume":"98","author":"Janikova","year":"2019","journal-title":"Ann Hematol"},{"key":"2026012223575830500_ref53","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"2026012223575830500_ref54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jjco\/hyae144","article-title":"Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study)","volume":"55","author":"Kita","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026012223575830500_ref55","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/blood.2020008825","article-title":"A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL","volume":"137","author":"Schmitz","year":"2021","journal-title":"Blood"},{"key":"2026012223575830500_ref56","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","volume":"134","author":"O'Connor","year":"2019","journal-title":"Blood"},{"key":"2026012223575830500_ref57","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"2026012223575830500_ref58","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","article-title":"Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma","volume":"7","author":"Ruan","year":"2023","journal-title":"Blood Adv"},{"key":"2026012223575830500_ref59","article-title":"Chidamide with azacitidine and CHOP treatment plus auto-ASCT for patients with newly diagnosed peripheral T-cell lymphoma: Interim analysis of a prospective, single-center, single-arm, phase 2 trial","volume":"P2106 [Abstract]","author":"Xiao","year":"2024","journal-title":"The European Hematology Association Congress"},{"key":"2026012223575830500_ref60","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.annonc.2023.08.013","article-title":"Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas","volume":"34","author":"Song","year":"2023","journal-title":"Ann Oncol"},{"key":"2026012223575830500_ref61","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","article-title":"Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 part B): A single-arm, multinational, phase 2 study","volume":"25","author":"Song","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026012223575830500_ref62","doi-asserted-by":"publisher","first-page":"PB3228","DOI":"10.1002\/smll.202507672","article-title":"Golidocitinib combined with CHOP in newly diagnosed peripheral T-cell lymphoma: Preliminary results from a phase 1\/2 clinical trial","author":"Zhang","year":"2025"},{"key":"2026012223575830500_ref63","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/S1470-2045(24)00502-3","article-title":"Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: A first-in-human, multicentre, open-label, single-arm, phase 1 study","volume":"25","author":"Maruyama","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026012223575830500_ref64","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026012223575830500_ref65","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","article-title":"Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): An open-label randomised, phase 3 study","volume":"11","author":"Dupuis","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026012223575830500_ref66","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"2026012223575830500_ref67","doi-asserted-by":"publisher","first-page":"112984","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: Results of the French AcS\u00e9-crizotinib trial","volume":"191","author":"Brugi\u00e8res","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026012223575830500_ref68","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1200\/JCO.22.00272","article-title":"Crizotinib in combination with chemotherapy for Pediatric patients with ALK+ anaplastic large-cell lymphoma: The results of Children\u2019s oncology group trial ANHL12P1","volume":"41","author":"Lowe","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/1\/24\/64602396\/hyaf158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/1\/24\/64602396\/hyaf158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T04:58:05Z","timestamp":1769144285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/1\/24\/8280156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,9]]},"published-print":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf158","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,9]]}}}